Corpus Intelligence IC Memo — UNIVERSITY OF MARYLAND MED SYS 2026-04-26 04:01 UTC
IC Memo — UNIVERSITY OF MARYLAND MED SYS
Investment Committee Memorandum | MD | 779 beds | Grade B | EBITDA uplift $136.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

UNIVERSITY OF MARYLAND MED SYS

CCN 210002 | BALTIMORE CITY, MD | 779 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

UNIVERSITY OF MARYLAND MED SYS is a 779-bed large academic medical center in BALTIMORE CITY, MD with $1.85B in net patient revenue and a -56.0% operating margin. The hospital serves a payer mix of 25.9% Medicare, 7.2% Medicaid, and 66.8% commercial.

Thesis: Undervalued. Our ML models identify $136.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -56.0% to -48.6% (+736bps).

Net Revenue HCRIS$1.85B
Current EBITDA COMPUTED$-1.04B
Operating Margin COMPUTED-56.0%
Occupancy HCRIS72.0%
Revenue / Bed COMPUTED$2.4M
Net-to-Gross HCRIS86.6%
Distress Probability ML50.6%

2. Market Context & Competitive Position

59
MD Hospitals
-8.3%
State Median Margin
431
Comparable Hospitals

MD has 59 Medicare-certified hospitals with a median operating margin of -8.3%. The target's margin of -56.0% places it below the state median. Among 431 size-comparable peers (390-1558 beds), the median margin is -4.5%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (390-1558), prioritizing same-state peers. 431 hospitals in the comp set.

HospitalStateBedsRevenueMargin
UNIVERSITY OF MARYLAND MED SYS (Target)MD779$1.85B-56.0%
ST. LUKES HOSPITALPA633$8.94B87.9%
STANFORD HEALTH CARECA657$6.76B3.7%
CLEVELAND CLINIC HOSPITALOH1326$6.38B-17.7%
VANDERBILT UNIVERSITY MEDICAL TN1084$5.44B-15.9%
UCSF MEDICAL CENTERCA834$5.44B-5.4%
UT MD ANDERSON CANCER CENTERTX721$4.90B-0.8%
UNIV OF MI HOSPITALS & HLTH CTMI951$4.62B-1.4%
MEMORIAL HOSPITAL FOR CANCER ANY514$4.34B-32.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $136.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$38.8M+210bp18mo
Cost to Collect4.5%2.5%$37.0M+200bp12mo
Denial Rate Reduction12.0%6.5%$36.6M+198bp12mo
A/R Days Reduction5200.0%3800.0%$22.5M+122bp9mo
Clean Claim Rate88.0%96.0%$1.2M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$38.8M
Cost to Collect
$37.0M
Denial Rate Reduction
$36.6M
A/R Days Reduction
$22.5M
Clean Claim Rate
$1.2M
Total EBITDA Uplift$136.2M
Current EBITDA$-1.04B
+ RCM Uplift+$136.2M
Pro Forma EBITDA$-899.5M
Current Margin-56.0%
Pro Forma Margin-48.6%
WC Released (1x)$71.0M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-1.59B$-5.47B0.00x-100.0%
Base (11x exit)10.0x11.0x$-1.59B$-6.53B0.00x-100.0%
Bull Case9.0x11.0x$-1.43B$-6.60B0.00x-100.0%
Bull (12x exit)9.0x12.0x$-1.43B$-7.63B0.00x-100.0%
Bear Case11.0x10.0x$-1.75B$-5.63B0.00x-100.0%
Bear (11x exit)11.0x11.0x$-1.75B$-6.77B0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 50.6% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 431 hospitals with 390-1558 beds
  • Same-state prioritization (n=7)
  • Comp margins: P25=-14.7% / P50=-4.5% / P75=4.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.